NEWSROOM

ALL Press Release Awards Media Center

Press Release

2024. 11. 20

Innorna Announces FDA Orphan Drug Designation Granted to IN015 for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Press Release

2024. 11. 13

Innorna Announces First Participant Dosed in Phase 1 Clinical Trial of Investigational Bivalent RSV mRNA Vaccine IN006

Press Release

2024. 11. 01

Innorna Announces U.S. FDA Rare Pediatric Disease Designation Granted to IN015 for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Press Release

2024. 07. 30

Innorna Announces Orphan Drug Designation Granted to IN016 for the Treatment of Progressive Familial Intrahepatic Cholestasis

Press Release

2024. 07. 23

Innorna Receives IND Clearance for IN001 Herpes Zoster mRNA Vaccine in China

Press Release

2024. 07. 19

Innorna Announces U.S. FDA Orphan Drug Designation Granted to IN022 for the Treatment of Homocystinuria

Press Release

2024. 07. 11

Innorna Announces U.S. FDA Rare Pediatric Disease Designation Granted to IN016 for the Treatment of Progressive Familial Intrahepatic Cholestasis

Press Release

2024. 07. 08

Innorna Announces U.S. FDA Rare Pediatric Disease Designation Granted to IN022 for the Treatment of Homocystinuria

Press Release

2024. 06. 05

Innorna receives IND clearance for its first-in-class bivalent RSV mRNA vaccine in China

Awards

2024. 04. 07

Innorna CEO Dr. Linxian Li Named as a 2024 In Vivo Rising Leader

Press Release

2024. 04. 17

Innorna's broad-spectrum SARS-CoV-2 mRNA vaccine receives Phase II clinical trial approval from FDA

2024. 02. 01

Innorna appointed Dr. Zhu Zhiqing as the Chief Technology Officer